• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    7/19/23 5:32:40 PM ET
    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDRX alert in real time by email

    Gainers

    • Dynatronics (NASDAQ:DYNT) stock moved upwards by 17.7% to $0.92 during Wednesday's after-market session. The market value of their outstanding shares is at $3.7 million.
    • Novan (NASDAQ:NOVN) shares rose 9.99% to $0.2. Trading volume for this security closed at 4.6 million, accounting for 680.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.6 million.
    • Trinity Biotech (NASDAQ:TRIB) shares moved upwards by 8.79% to $1.11. The company's market cap stands at $42.4 million.
    • 9 Meters Biopharma (NASDAQ:NMTR) shares moved upwards by 8.32% to $0.18. 9 Meters Biopharma's trading volume hit 901.9K shares by close, accounting for 392.3% of its average volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares increased by 7.69% to $0.05. Trading volume for this security closed at 14.5 million, accounting for 163.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.0 million.
    • Oncternal Therapeutics (NASDAQ:ONCT) shares increased by 6.48% to $0.46. The company's market cap stands at $27.0 million.

    Losers

    • Healthcare Triangle (NASDAQ:HCTI) shares declined by 8.1% to $4.41 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 79.4K shares, which is 9.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $18.8 million.
    • EUDA Health Holdings (NASDAQ:EUDA) stock decreased by 8.07% to $0.51. The market value of their outstanding shares is at $12.6 million.
    • Enochian BioSciences (NASDAQ:ENOB) stock declined by 7.97% to $0.56. The company's market cap stands at $35.6 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock fell 7.7% to $5.16. The company's market cap stands at $1.2 million.
    • Trevena (NASDAQ:TRVN) stock fell 6.87% to $0.95. The market value of their outstanding shares is at $10.4 million.
    • Evelo Biosciences (NASDAQ:EVLO) shares decreased by 6.23% to $6.09. Evelo Biosciences's trading volume hit 97.8K shares by close, accounting for 13.5% of its average volume over the last 100 days. The company's market cap stands at $114.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDRX
    $DYNT
    $ENOB
    $EUDA

    CompanyDatePrice TargetRatingAnalyst
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$5.00Buy
    BTIG
    Oncternal Therapeutics Inc.
    $ONCT
    2/24/2022$50.00Buy
    BTIG
    Evelo Biosciences Inc.
    $EVLO
    11/2/2021$44.00 → $41.50Market Outperform
    JMP Securities
    Evelo Biosciences Inc.
    $EVLO
    11/1/2021$12.00Neutral → Buy
    Chardan Capital Markets
    Novan Inc.
    $NOVN
    9/24/2021$28.00 → $24.00Buy
    HC Wainwright & Co.
    Novan Inc.
    $NOVN
    7/9/2021$30.00Overweight
    Cantor Fitzgerald
    9 Meters Biopharma Inc.
    $NMTR
    7/8/2021$5.00Outperform
    BMO Capital Markets
    More analyst ratings

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

    April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s

    4/2/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a

    4/1/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Murphy Paul

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:15:37 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Tivnan John Paul

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:14:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Gillard John

    3 - TRINITY BIOTECH PLC (0000888721) (Issuer)

    4/3/26 8:11:38 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

    Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

    2/8/24 7:21:49 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG initiated coverage on Oncternal Therapeutics with a new price target

    BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $5.00

    2/24/22 7:15:03 AM ET
    $ONCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG initiated coverage on Oncternal Therapeutics with a new price target

    BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $50.00

    2/24/22 7:15:03 AM ET
    $ONCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wills Robert James bought $27,655 worth of shares (3,086 units at $8.96), increasing direct ownership by 45% to 10,000 units (SEC Form 4)

    4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)

    4/10/24 8:38:22 PM ET
    $ONCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wills Robert James bought $58,602 worth of shares (6,914 units at $8.48) (SEC Form 4)

    4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)

    4/1/24 7:00:13 PM ET
    $ONCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hale David F bought $8,859 worth of shares (980 units at $9.04) (SEC Form 4)

    4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)

    2/27/24 5:03:15 PM ET
    $ONCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    SEC Filings

    View All

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    4/2/26 4:28:29 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    4/2/26 4:28:28 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    4/2/26 4:28:29 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

    Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced version of its EpiCapture™ prostate cancer test, engineered to deliver higher precision risk prediction of aggressive prostate cancer. This next-generation version of EpiCapture™ utilizes machine learning tools that integrate additional patient features, including patient ethnicity in conjunction with the DNA biomarkers

    3/23/26 9:23:07 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

    Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column

    3/12/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BDRX
    $DYNT
    $ENOB
    $EUDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care